Drug intelligence / Profile preview

68Ga-NY129

Development stage: Preclinical
Lead developer: Norroy Bioscience
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
Administration: Intravenous

Overview

68Ga-NY129 is an investigational gallium-68-labeled radiopharmaceutical being developed by Norroy Bioscience for positron emission tomography (PET) imaging of prostate cancer. It is designed to target acid phosphatase 3 (ACP3), also known as prostatic acid phosphatase (PAP), which is highly expressed in prostate cancer cells. As a diagnostic PET tracer, 68Ga-NY129 enables non-invasive molecular imaging to detect and characterize prostate cancer lesions, serving as the diagnostic partner in a theranostic pair alongside its therapeutic counterpart, 177Lu-NY129.

Other names: 68Ga-NY-129Ga-68 NY129Ga68 NY129Ga 68 NY129Ga-68-NY129Ga68-NY129Ga 68-NY129

Targets

PAP (Prostatic acid phosphatase)

Beyond the preview

Go deeper on 68Ga-NY129.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 68Ga-NY129.